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As the incidence of cancer continues to rise, the use of radiotherapy has emerged as a leading treatment modality.
Preclinical models in radiation oncology are essential tools for cancer research and therapeutics. Various model
systems have been used to test radiation therapy, including in vitro cell culture assays as well as in vivo ectopic and
orthotopic xenograft models. This review aims to describe such models, their advantages and disadvantages,
particularly as they have been employed in the discovery of molecular targets for tumor radiosensitization.
Ultimately, any model system must be judged by its utility in developing more effective cancer therapies, which is
in turn dependent on its ability to simulate the biology of tumors as they exist in situ. Although every model has its
limitations, each has played a significant role in preclinical testing. Continued advances in preclinical models will
allow for the identification and application of targets for radiation in the clinic.
Keywords: Preclinical models, Radiation oncology, Radiosensitizer, Orthotopic xenograft modelBackground
It is estimated that in 2012 that there will be 1.6 million
non-skin cancers diagnosed in North America; nearly
three fourths of these cancer patients will receive radi-
ation therapy sometime during the course of their illness
[1]. Because radiotherapy continues to serve as a primary
cancer treatment modality, the development of strategies
that improve its efficacy could benefit a significant num-
ber of patients. Whereas most improvements in tumor
control achieved in the past 30 years of radiation oncol-
ogy can be attributed to advances in dose delivery tech-
nology, further improvements will likely depend on a
greater understanding of the biology underlying tumor
response to radiation. More specifically, it is generally
considered that the delineation of the fundamental
mechanisms mediating tumor cell radioresistance will
lead to the identification of molecules that can serve as
targets for radiosensitization. Such information will pro-
vide the basis for the development of clinical protocols
combining molecularly targeted agents and radiotherapy.
Towards this end, laboratory studies have implicated
more than 70 molecules as potential determinants of
tumor cell radiosensitivity, with additional molecules iden-
tified every year [2]. Thus, there is no shortage of putative* Correspondence: camphauk@mail.nih.gov
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reproduction in any medium, provided the ormolecular targets for radiosensitization. However, transla-
tion of these data into clinically relevant targets for cancer
radiotherapy requires more than establishing a causal rela-
tionship between a molecule and the radiosensitivity of a
given tumor cell line: additional information is required.
Clearly, whether the target is selective for the radiosensiti-
zation of tumor over normal cells should be determined.
An additional and more difficult question, regards cellular
context. It is often the case for tumor selective targets
that they influence the radiosensitivity of some tumor
cells, but not others. Defining the genetic, epigenetic and
microenvironmental circumstances, i.e. cellular context,
in which a molecule functions as a determinant of radio-
sensitivity would be of considerable value in the develop-
ment of successful clinical applications. Establishing
causal relationships, tumor selectivity and cellular context
in a relevant preclinical setting requires the use of a
number of experimental models. The goal of this review
is to describe the model systems currently employed in
research efforts aimed at developing molecular targets for
tumor radiosensitization.In Vitro culture systems
Cells grown in monolayer cultures provide an experi-
mentally expedient model for cancer research in general
and have been used extensively in defining the molecular
determinants of radiosensitivity. Cell culture experi-
ments typically comprise the initial step in establishing ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kahn et al. Radiation Oncology 2012, 7:223 Page 2 of 5
http://www.ro-journal.com/content/7/1/223causal relationship between a suspected molecular deter-
minant and radiosensitivity as well as the preliminary
evaluation of drug/radiation combinations. In this model
system radiosensitivity is most rigorously defined using
the clonogenic survival assay, which measures the prolif-
erative (clonogenic) capacity of individual cells. In the
most commonly used form of this assay, single cell sus-
pensions are seeded into tissue culture plates, allowed to
attach and irradiated; colonies are then counted after
10-21 days, depending on the specific cell line [3]. The
minimum colony size is typically set at 50 cells, which
coincides with 5-6 doublings. The necessity for colony
formation, which involves a relatively prolonged time
period between irradiation and analysis of cell death
(defined as the loss of reproductive potential), is based
on the fundamental mechanisms of radiobiology. For
most solid tumor cells, as well as for fibroblasts, the pri-
mary mode of cell death after radiation exposure is mi-
totic catastrophe, which can require several cell divisions
for maximal expression. Moreover, radiation induces
transient growth arrest, which can be misinterpreted as
cytotoxicity in short term assays based on cell number.
With respect to detecting modifications in radiosensitiv-
ity, targeting of molecular determinants can potentially
switch the mode of death from mitotic catastrophe to
apoptosis or autophagy; each form of death is accounted
for in the clonogenic survival assay. Thus, the gold
standard for quantifying radiosensitivity and its modifi-
cation is clonogenic survival analysis.
An additional advantage of cell culture models is the cap-
acity for the molecular manipulation of suspected determi-
nants of radiosensitivity (Figure 1). Standard molecular
techniques using genetic and epigenetic approaches have
traditionally been combined with the clonogenic survival
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Figure 1 Limitations and advantages of preclinical model systems intarget and radiosensitization. Furthermore, analyses of such
processes as cell cycle phase distribution, DNA DSB induc-
tion and repair, and of the mode cell death (apoptosis, mi-
totic catastrophe or autophagy) provide insight into the
mechanism through which the molecule in question affects
radioresponse. Cell culture models have also been used in
the initial evaluation of whether a molecularly targeted
agent acts in a predictable fashion. For example, our lab has
previously performed experiments using the HDAC inhibi-
tor valproic acid [4]. Using immunoblots generated from
monolayer cultures, valproic acid was shown to induce
hyper-acetylation of histone H3 or H4, and this hyperacety-
lation was dependant on continuous drug exposure. Clono-
genic survival analysis then showed that continuous
exposure of cells to valproic acid was necessary to achieve
the maximum enhancement of radiation induced cell death,
consistent with the dependence on continuous drug expos-
ure exhibited by histone hyperacetylation.
Numerous studies aimed at defining the molecular
determinants of radiosensitivity have initially been per-
formed using in vitro monolayer cultures. Comparison
of tumor cell lines to normal cell lines such as fibro-
blasts or mammary epithelial cells provides for an initial
evaluation of whether a molecular determinant and/or a
targeted agent selectively enhance the radiosensitivity of
tumor cells over normal cells. Using multiple tumor cell
lines across various histologies may provide a system for
investigating cell the genetic and epigenetic context
under which a molecule regulates radiosensitivity.
Although essential to establishing causal relationships
between a molecule and radiosensitivity, i.e., identifying
molecular targets, the use of in vitro model systems is
not without limitations. First, the use of in vitro systems
is based on the assumption that the phenotype of tumor
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tive. Many commonly used human tumor cell lines have
been maintained on plastic in the laboratory for years,
allowing for additional unwanted selection pressures;
thus, the cell lines may not be representative of the ori-
ginal tumor in situ. In a recent study, Shai et al. showed
by microarray analysis that tumor cells grown for three
passages on plastic were no longer representative of the
in situ tumors from which they were derived [5]. Fur-
thermore, cells grown in vitro lack the architectural and
cellular complexity of in vivo tumors including inflam-
matory, vascular, and stromal components [6], factors
that can influence tumor radioresponse.
In vivo models
Both rodent and human cells have been used to investi-
gate in vivo tumor radioresponse. Most rodent cell stud-
ies have focused on implanted murine or rat syngeneic
tumors, although more recently genetically engineered
mouse (GEM) models have been used to evaluate the
radioresponse of spontaneous tumors [7-9]. The primary
model for investigating the radioresponse of human
tumor cells under in vivo conditions involves their im-
plantation and growth in immunocompromised mice or
rats [10]. Whereas both rodent and human tumor mod-
els are available, studies aimed at developing molecularly
targeted radiosensitizing agents have been primarily per-
formed using human tumor cells. The rationale, as re-
cently summarized by Olive and colleagues, is that there
are significant differences between rodent and human
cells in terms of the fundamental processes regulating
radioresponse [11]. Studies performed over the years
have shown that the activities and/or levels of critical
molecules mediating the DNA damage response after ir-
radiation such as DNA-PK, Ku70, Ku86 and NBS differ
between species. Moreover, in terms of general pro-
cesses, rodent cells are more susceptible to radiation-
induced oncogenic transformation, less efficient at
checkpoint activation, and more sensitive to oxidative
stress as compared to human cells. Given the differ-
ences between rodent and human cells regarding
aspects of the fundamental mechanisms mediating cel-
lular response and given that a goal of experimental
radiation oncology is to develop modifiers relevant to
treatment, most preclinical radiation studies focus on
human tumor xenografts. However, it should be noted
that the human tumor xenograft model does have a
number of potentially significant limitations, which in-
clude the absence of an immune response and the
presence of mouse rather than human stroma. Clearly,
depending on the molecular target being addressed
and its mechanism of action, these characteristics need
to be taken into account when attempting to translate
results to a clinical situation.The most common assay used in defining in vivo
radioresponse is the tumor growth delay (TGD) assay
[3]. Typically, tumor cells, regardless of tissue of origin,
are implanted subcutaneously on the leg. This site, in
contrast to the flank, allows for delivery of radiation to
the tumor without exposing critical organs. After im-
plantation, the tumor is allowed to grow to a measurable
volume, the mice are randomized, and therapy is
initiated. Tumor volumes are then measured 2-3x
weekly with data plotted as the mean of the volumes.
However, each tumor should be measured and tracked
separately, as the TGD is calculated for each tumor and
reported as the difference between the control and ex-
perimental group as days delay +/- SEM. Advantages of
the leg TGD model include expedient implantation, rela-
tively straightforward volume measurements and min-
imal impact on the overall wellbeing of the mouse,
which limits the introduction of complicating variables.
The primary disadvantage is that the microenvironment
does not simulate that of the in situ tumor.
To account for the potential influence of tumor spe-
cific microenvironments, another in vivo model used in
experimental radiation oncology is the orthotopic im-
plant of tumor cells. This technique has been applied to
the radiation response of pancreas, lung, breast, prostate
and brain tumors. Our laboratory focuses on brain
tumors, as such; we commonly do orthotopic implants
of human GBM cells into the brains of nude mice [12].
To perform this technique, a stereotactic apparatus is used
to implant tumor cells into a specific area of the brain.
Typically, bioluminescent imaging or magnetic resonance
imaging can be used to confirm both presence and volume
of tumor before initiating the experimental therapy. Irradi-
ation is performed using a customized jig that allows ir-
radiation of the tumor but shields the remainder of the
mouse. Once the therapy has begun, the most common
endpoint is survival and a Kaplan-Meier curve is generated
to determine significance of each therapy. The main advan-
tage of the use of orthotopic tumors is that the microenvir-
onment may more closely represent that of the in situ
tumor. The disadvantages are the difficultly and skill
required to perform the implants, the difficulty of imaging
tumors and the impact the tumor implant has on the organ
function of the mouse.
In vitro vs. ectopic vs. orthotopic models
As described above, each model system used in the de-
velopment of molecular targets for radiosensitization has
advantages and disadvantages. However, the ultimate
utility of a given model to the development of more ef-
fective cancer therapies depends on its ability to simu-
late the phenotype of tumor cells as they exist in situ.
To begin to address this issue, our lab has used gene ex-
pression profiling as an indicator of phenotype to
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grown in vitro as a monolayer and in vivo as subcutane-
ous leg and as intracranial xenograft tumors [13]. For
each cell line, the gene expression profile generated from
tissue culture was significantly different from that gener-
ated from the subcutaneous tumor, which was signifi-
cantly different from those grown intracranially (i.c.).
The U251 and U87 gene expression profiles generated
under the three growth conditions were also compared
to one another. As expected, the profiles of the two gli-
oma cell lines were significantly different from each
other when grown as monolayer cultures. However, the
expression profiles for the glioma cell lines were less dis-
cordant when grown as subcutaneous tumors, and actu-
ally similar when grown as intracranial tumors. Using
Statistical Analysis of Microarray software, we also
showed that the two cell lines had 290 genes that were
common outliers in the orthotopic environment com-
pared to the in vitro growth environment (SAM ref).
Using the GOStat program, the 290 outlier genes were
mapped to functions of central nervous system develop-
ment and CNS function (GoSTAT ref ). These data sug-
gest that the microenvironment has a significant impact
on the phenotype of the tumor model and thus the po-
tential response to cytotoxic therapy. This work has
been expanded, by additional investigators, to tumors
from different in situ environments including model sys-
tems of ovarian tumors, meduloblastoma, head and neck
cancers and lung cancers [14-17].
To determine if the tumor model microenvironment had
an effect on the response to radiation therapy we next irra-
diated U87 and U251 cells as monolayer cultures, as ec-
topic flank tumors and as orthotopic tumors and collected
the tumors for cDNA microarray analysis [18]. The com-
parison of the arrays for the in vitro samples showed very
few changes at the mRNA level as well as very few com-
mon changes between the cell lines. However, in the sam-
ples from the orthotopic tumors there were over 700
common genes that significantly changed after therapy in
both cell lines. These data suggest that whereas genotype
may be the overwhelming determinant of radiosensitivity
for cultured cells, under i.c. conditions the brain micro-
environment plays a significant role in regulating the genes
affected by radiation. Similar results have been obtained by
other investigators using an alternate GBM model as well
as an orthotopic pancreas model [19,20]. Thus, taking into
account such environmental influences will likely be crit-
ical in defining the putative functional significance of
radiation-induced changes in gene expression when com-
paring different model systems.
However, results showing the differences between model
systems do not directly address the central question of
which model system is most similar to the in situ tumors.
Currently, there is no biopsy data from patients undergoingradiotherapy after one or several doses of radiation. How-
ever, several datasets exist of resected GBM samples studied
by microarray profiling [21,22] Shankavaram and colleagues
recently completed a comparison of three model systems
and the clinical dataset published by Bredel et al. [23]. The
data from both the in vitro and ectopic in vivo samples
were not highly correlated with any of the primary GBM
samples. However, the data from the orthotopic samples
was highly correlated to a subset of the entire clinical data-
base that involved genes and pathways related to neurogen-
esis and growth factor-induced signal transduction.
Moreover, using the combined clinical and experimental
datasets, glutamate receptor was suggested as a potential
target for radiosensitization unique to the orthotopic sys-
tem. That is, treatment with the glutamate receptor inhibi-
tor LY341595 was shown to enhance the radiosensitivity of
glioma cells grown in the orthotopic model, but not in ei-
ther the in vitro or ectopic tumor models. Thus, these
results suggest that the orthotopic tumors represented a
subset of the samples collected from patients with GBM
and that this subset can be used to discover a novel target
for GBM radiosensitization, information that could not be
generated from the more standard glioma models of
in vitro monolayer culture and subcutaneous xenografts.Conclusion
The current state of the art in preclinical modeling in radi-
ation oncology research involves the use of in vitro cultures
and assays, as well as ectopic and orthotopic xenograft
models. As investigators initiate pre-clinical experiments,
analysis of the genetics of the cell lines used the compos-
ition of the microenvironment and the experimental tech-
niques available should be evaluated and compared to the
proposed disease to be treated in the clinic.
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